Targeting the liver: Insights from a tertiary center on post-operative hepatic arterial oxaliplatin for metastatic colorectal cancer - PubMed
4 days ago
- #Hepatic Arterial Infusion Chemotherapy
- #Liver Metastases
- #Colorectal Cancer
- Study investigates hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin post-resection of colorectal liver metastases (CRLM).
- Retrospective analysis of 119 patients (median age 56, 82% synchronous metastatic disease) treated between 2008-2022.
- Median disease-free survival (DFS) was 10.2 months; intrahepatic DFS was 18.4 months.
- Median overall survival (OS) reached 55.5 months with a 5-year OS rate of 46%.
- Grade 3-4 toxicities occurred in 45% of patients; 54% experienced pain during infusion.
- HAIC with oxaliplatin is deemed effective, safe, and feasible for CRLM treatment post-resection/ablation.